• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Organisation › Details

Ci3 Cluster (Cluster für Individualisierte ImmunIntervention e. V.)

The CI3 excellence cluster pools the outstanding expertise in the Rhine-Main cluster region of Germany involving innovative new therapies and diagnostics in the field of individualised immune intervention. To this end, CI3 is putting together a network of players from the business, research and healthcare communities as well as government and is shaping the integral element across the entire innovation and value creation chain. *

 

	Start	2011-04-14 existent
	Industry	pharmacogenomics/pharmacogenetics
	Person	Türeci, Özlem (Ganymed 200811 CEO + CSO)
	Person 2	Wessel, Rainer (DKFZ 201906– before CI3 Cluster Manager before Ganymed CEO)
	Region	Mainz
	Country	Germany
	Street	17–19 Kupferbergterrasse
	City	55116 Mainz
	Tel	+49-6131-6230581
		Address record changed: 2018-07-24
Basic data	Employees	n. a.
		* Document for �About Section�: Zedira GmbH. (6/25/12). "Press Release: Zedira, Dr. Falk Phama and the University of Mainz Hospital, which Together Comprise a Flagship Project of the CI3 Excellence Cluster, Are to Receive Subsidy Funding for Clinical Development of a Celiac Disease Dru
		Record changed: 2018-10-31

Advertisement

More documents for Ci3 Cluster (Cluster für Individualisierte ImmunIntervention e. V.)

• [1] Cluster für Individualisierte ImmunIntervention (Ci3) e. V.. (8/1/17). "Press Release: Collaboration Project between German Biotech and IT Companies Selected for Funding in First PERMIDES Round of Call"....
• [2] Zedira GmbH. (10/20/15). "Press Release: Zedira, Dr. Falk Pharma and the University of Mainz Hospital, which Together Comprise a Flagship Project of the Ci3 Leading-edge Cluster, Are to Receive Additional Subsidy Funding for Clinical Development of a Cel...
• [3] Biotest AG. (3/27/14). "Press Release: Biotest AG Initiates Clinical Study with Indatuximab Ravtansine (BT-062) in Solid Tumors". Dreieich....
• [4] Cluster für Individualisierte ImmunIntervention (Ci3) e. V.. (11/19/13). Web Site: Partner. [http://www.ci-3.de, 11/19/13]...
• [5] Cluster für Individualisierte ImmunIntervention (Ci3) e. V.. (7/21/13). Web Site: Partner – Impressum. [http://www.ci-3.de, 07/21/13]...
• [6] Universität Mainz. (12/7/12). "Pressemitteilung: Ausgründungen aus der Universitätsmedizin Mainz feiern Richtfest des neuen Mainzer Biotech-Forschungszentrums"....
• [7] Biotest AG. (7/16/12). "Press Release: Biotest AG Starts Combination Therapy Study with BT-062 in Multiple Myeloma. Antibody-drug Conjugate BT-062 Continues to Show Good Tolerability in Monotherapy". Dreieich....
• [8] Zedira GmbH. (6/25/12). "Press Release: Zedira, Dr. Falk Phama and the University of Mainz Hospital, which Together Comprise a Flagship Project of the CI3 Excellence Cluster, Are to Receive Subsidy Funding for Clinical Development of a Celiac Disease Dru...
• [9] Biotest AG. (3/22/12). "Press Release: BT-062 Demonstrates Rapid and Complete Tumor Eradication in Preclinical Studies. Pronounced Anti-tumor Activity against Aggressive Solid Tumors". Dreieich....
• [10] Cluster für Individualisierte ImmunIntervention (Ci3) e. V.. (1/19/12). "Pressemitteilung: Rhein-Main Immuntherapie-Cluster CI3 erfolgreich im Spitzencluster-Wettbewerb. Mehr als 80 Million Euro Förderung für die Entwicklung indivdualisierter Immuntherap...

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2019. Made in Germany.